SkyePharma's lung drug approved in Japan; Cyclacel presents positive data for ovarian cancer treatment;

@FierceBiotech: ICYMI yesterday - Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article | Follow @FierceBiotech

@JohnCFierce: Bind (Langer) raised $70.5M in its IPO. Priced in the range. Press release | Follow @JohnCFierce

@EmilyMFierce: A molecular decoy could treat the most common type of human dwarfism. More via Science | Follow @EmilyMFierce

> SkyePharma's asthma therapy Flutiform has been approved in Japan. Item

> Cyclacel Pharmaceuticals ($CYCC) unveiled new data at the American Association of Cancer Research conference today showing that sapacitabine is effective against a majority of ovarian cancer samples taken from patients, including resistant tumors. Release

> Vivus ($VVUS) said it has submitted a request to the European Medicines Agency (EMA) for scientific advice regarding use of an interim analysis to support its resubmission of the marketing authorization application for European approval of its obesity drug Qsiva. Release

Medical Device News

@FierceMedDev: Covidien plots job cuts, plant closures to save $300M. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Ocular Therapeutix inches toward FDA approval with a panel thumbs-up. Story | Follow @DamianFierce

@MarkHFierce: A jury awarded Retractable Technologies $100M-plus in a patent lawsuit verdict against Becton Dickinson. Release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an  with a continuous glucose monitor. Who will get one to market first? Special report from FierceDrugDelivery | Follow @MichaelGFierce

> Sapheon begins PMA process for varicose vein treatment. Story

> J&J vaginal mesh class-action suit grows in Australia. Item

> Baxter recalls caps over deadly embolism risk. Article

Pharma News

@FiercePharma: Sanofi CEO: Thanks to Genzyme, investors take us seriously. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Ranbaxy's hair in tablet issue will shave its Q3 earnings, analyst tells ETReport | Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Purdue hands California list of risky OxyContin prescribers. Article Follow @CarlyHFierce

> India court allows J&J to resume production at plant ordered closed 3 months ago. Report

> GSK gets double dose of good news for Breo Ellipta. Story

> Sanofi rids itself of Zimulti suit, but its legacy weighs on new-generation obesity pills. More

And Finally... Personalized medicine, new diagnostic tests and tailored treatments are ushering in a new era of cancer care. Story

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.